Lilly Drug Receives Approval in Japan

Posted: Updated:
INDIANAPOLIS -

The Japan Ministry of Health, Labor and Welfare has granted Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Delaware-based Incyte Corp. (Nasdaq: INCY) marketing approval for a once-daily treatment of rheumatoid arthritis. Lilly says the approval for Olumiant is based on four phase 3 clinical trials.

The approval is for 2-mg and 4-mg tablets of Olumiant, also known as baricitinib, which Lilly says will be used by patients with inadequate responses to standard-of-care therapies. The pharmaceutical company says the clinical trials included more than 3,000 moderate-to-severe RA patients throughout the world, including more than 500 from Japan.

"Today is an important milestone for the RA community in Japan," said Christi Shaw, president of Lilly Bio-Medicines. "Olumiant has been shown to provide effective relief of RA symptoms in people who do not respond to standard treatments, as well as prevent the structural damage to joints that makes RA a progressive, debilitating disease."

Lilly says the approval triggers a $15 million milestone payment from Lilly to Incyte, which is expected to occur in the third quarter.

Earlier this year, the U.S. Food and Drug Administration rejected a new drug application for the treatment, saying more clinical results were needed. 

  • Perspectives

    • The Evolution of Business: From Bottom Line to Value Creation And Impact

      In today's world, consumers want to know how corporations, as a whole, are taking a stand. In fact, customers are 43 percent more likely to purchase a product from a company they know is committed to social value. It's not just consumers pushing this trend. Financial service industry leaders, like KeyBank's Beth Mooney and BlackRock's Larry Fink, are challenging business owners and the C-Suite to rethink their economic impact, environmental footprint and social conscience.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Indy Firm Taps Appirio Exec as CEO

      An Indianapolis-based design and innovation consulting firm has named a new chief executive officer. Studio Science says Steve Pruden, who most recently served as senior vice president of human resources with Indy tech company Appirio, will lead the company.

    • Court Sides With Lilly on Alimta Case

      The latest in a string of patent infringement cases involving Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has ended positively for the pharmaceutical giant. The U.S. District Court for the Southern District of Indiana has ruled in favor of Lilly, preventing a competitor from launching an alternative form of its Alimta vitamin regimen. The court ruled that Lilly's patent for Alimta would be infringed upon if India-based Dr. Reddy's Laboratories had moved forward with...

    • St. Vincent Announces Layoffs

      St. Vincent Health says it has laid off 85 employees throughout the state. In a statement to Inside INdiana Business, St. Vincent cites a rapidly-evolving healthcare environment as a reason for the workforce reduction. 

    • (Image Courtesy: Lilly Oncology)

      Lilly Closes on Mega Acquisition

      Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has completed its acquisition of ARMO BioSciences Inc. of California. The deal, which was valued at approximately $1.6 billion when first announced last month, boosts Lilly's immuno-oncology pipeline. Lilly offered $50 per share of ARMO stock for the company. ARMO's portfolio includes...

    • Auburn City Hardware Store Sold

      A historic northeast Indiana retailer is under new ownership. The KPC News reports the Auburn City Hardware Store has been sold to VRJ Holdings, which is also based in DeKalb County.